Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence

Efficacy and Safety Evaluation of Immune Checkpoint Inhibitors in Combination With Chemotherapy for Extensive Small Cell Lung Cancer: Real‐World Evidence

ABSTRACT Introduction Extensive small cell lung cancer (ES‐SCLC) are currently managed using first‐line chemotherapy options, including atezolizumab (Atezo) plus etoposide and carboplatin (CE) or durvalumab (Durva) plus etoposide with either cisplatin (PE) or carboplatin (CE). However, a definitive...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuta Yamanaka, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi, Yume Sanada, Kiyori Yoshida, Tatsuki Ikoma, Yuki Takeyasu, Utae Katsushima, Hiroshige Yoshioka, Takayasu Kurata
Format:	Article
Language:	English
Published:	Wiley 2024-12-01
Series:	Cancer Medicine
Subjects:	atezolizumab durvalumab extensive‐stage small cell lung cancer first‐line treatment immune checkpoint blockade real‐world evidence
Online Access:	https://doi.org/10.1002/cam4.70480
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparative Study on Associations Between Lung Cancer Prognosis and Diagnostic Criteria Set by the European Palliative Care Research Collaboration and the Asian Working Group for Cachexia
by: Utae Katsushima, et al.
Published: (2025-01-01)

The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01)

Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real‐World Clinical Study
by: Shun Kaneko, et al.
Published: (2025-09-01)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023-08-01)

Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization
by: Maaz Khan Afghan, et al.
Published: (2024-10-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01)

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
by: Sun Young Yim, et al.
Published: (2024-10-01)

A Case of Fibrolamellar Hepatocellular Carcinoma in Which Tumor Control Was Achieved by Re‐Administering Atezolizumab and Bevacizumab
by: Satoru Hagiwara, et al.
Published: (2024-12-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01)

Esophagitis and Pneumonitis Related to Concurrent Chemoradiation ± Durvalumab Consolidation in Unresectable Stage III Non-Small-Cell Lung Cancer: Risk Assessment and Management Recommendations Based on a Modified Delphi Process
by: Anthony M. Brade, et al.
Published: (2024-10-01)

Efficacy of subsequent treatment for unresectable locally-advanced non-small cell lung cancer after relapse of concurrent chemoradiotherapy with durvalumab consolidation therapy: A single-center retrospective study
by: Yuichiro Nishibori, et al.
Published: (2024-01-01)

Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US
by: Yingtao Lin, et al.
Published: (2024-11-01)

Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis
by: Bi-Cheng Wang, et al.
Published: (2024-12-01)

High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab
by: Ciani Ellison, MD, et al.
Published: (2024-12-01)

Descriptive analysis of durvalumab use in unresectable stage III non-small cell lung cancer in patients treated in Quebec’s University teaching hospitals
by: Valérie Labrie, et al.
Published: (2024-12-01)

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
by: Jason C.S. Ho, et al.
Published: (2024-01-01)

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
by: Ginette S. Santiago-Sánchez, et al.
Published: (2024-12-01)

J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan
by: Eisaku Miyauchi, MD, PhD, et al.
Published: (2025-03-01)

Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
by: Mauro Zukin, et al.
Published: (2025-01-01)

Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab
by: Jaejun Lee, et al.
Published: (2024-12-01)

Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18
by: Dae-Ho Choi, MD, et al.
Published: (2024-12-01)

Comparative effectiveness of anterior and posterior approaches for interscalene brachial plexus block: a systematic review and meta-analysis
by: Luis Eduardo Ciconini, et al.
Published: (2025-01-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
by: Nils-Petter Rudqvist, et al.
Published: (2023-12-01)

Clinical Use of Dostarlimab in Advanced Stage and Recurrent Endometrial Cancer: Patient Selection and Perspectives
by: Bujnak AC, et al.
Published: (2025-01-01)

Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death
by: Peng Liu, et al.
Published: (2024-12-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors
by: Michael S. Chang, MD, et al.
Published: (2025-02-01)

Improved survival with second-line hepatic arterial infusion chemotherapy after atezolizumab-bevacizumab failure in hepatocellular carcinoma
by: Ji Yeon Lee, et al.
Published: (2024-12-01)

Three effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report
by: Koji Rinka, et al.
Published: (2025-01-01)

Clinical characteristics, diagnosis, treatment, and prognosis of Atezolizumab-induced encephalitis, aseptic meningitis or meningoencephalitis
by: Qingzi Yan, et al.
Published: (2025-01-01)

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment
by: Young Eun Chon, et al.
Published: (2023-02-01)

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
by: Young Eun Chon, et al.
Published: (2024-10-01)